Can a new daily pill offer safer Long-Term control of schizophrenia?

NCT ID NCT07759869

Not yet recruiting Disease control Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This phase 3 trial is testing the long-term safety of an oral drug called HS-10380 in Chinese adults with schizophrenia. Over about a year, 500 participants will take the medication daily, with doses adjusted to an optimal level. The study tracks side effects, serious adverse events, and how well the drug controls symptoms. The goal is to see if HS-10380 can be a safe, ongoing treatment option for managing schizophrenia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-10380, an oral antipsychotic drug taken once daily
What this could lead to: If successful, this could support HS-10380 as a long-term treatment option for schizophrenia, potentially offering better safety or tolerability.
What could go wrong: This is an open-label study without a placebo, so results may be biased. Long-term safety and effectiveness are still uncertain, and side effects may emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia schizophrenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA 1 (DISORDER)

Contacts and locations

Locations

Peking University Sixth Hospital

Beijing, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.